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36

Summary:

37

Spontaneous interferon-γ (IFNγ) released detected by enzyme-linked immunospot

38

(ELISpot) assays may be a biological phenomenon. Markers of immune activation

39

levels were assessed as correlates of high background among individuals in Kenya.

40

Couples concordantly seronegative for HIV-1 were enrolled. IFN-γ ELISpot assays were

41

conducted and negative control wells were categorized as having either high or low

42

background (≥50 and <50 SFU/106 peripheral blood mononuclear cells (PBMC),

43

respectively). PBMC were stained for CD4, CD8, and immune activation markers (CD38

44

and HLA-DR) and analyzed using flow cytometry. Proportions of activated T-cells were

45

compared between those with low and high background by Mann-Whitney U test.

46

Correlates of background SFU and immune activation were assessed using regression

47

models. Among 58 individuals, 14 (24%) had high background. Frequencies of

48

CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells were higher in individuals with

49

high background compared to those with low background (p=0.02). Higher background

50

SFU was associated with history of sexually transmitted infections (p=0.03), and illness

51

in the past 3 months (p=0.005), in addition to increased levels of activated CD4+ and

52

CD8+ cells (p range=0.008-0.03). Female gender and male circumcision decreased

53

levels of CD4+ and CD8+ immune activation (p range=0.002-0.03). Additionally, higher

54

background SFU and activated CD4+ and CD8+ cells were individually associated with

55

positive ELISpot responses to HIV-1 peptide pools (p range=0.01-0.03). These findings

56

suggest that increased basal immune responses may be a biological mechanism

57

contributing to higher background ELISpot SFU. Systematic exclusion of data from

3
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58

individuals with increased background in IFN-γ release assays may bias results in

59

population-based studies.

60
61

Keywords: ELISpot; interferon gamma; IGRA, immune activation; flow cytometry, CD4,

62

CD8, HLA-DR, CD38
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63
64

Introduction:
The IFN-γ enzyme-linked immunospot (ELISpot) assay is widely used to quantify

65

viral, tumor, allo- and auto-antigenic cellular immune responses in clinical and vaccine

66

trials. This assay is quick, cost-effective and one of the most sensitive methods to

67

detect antigen-specific T cell responses {Schmittel, 1997 #1657;Schmittel, 2001 #235}.

68

Quality of ELISpot assay results depends on accurate detection of spot forming units

69

(SFU) through good staining that allows discrimination of specific spots (signal) from

70

non-specific background spots (noise). Therefore, it is necessary to minimize

71

background SFU in negative control wells and to maximize antigen-induced spots in

72

experimental wells to optimize the signal-to-noise ratio.

73

Methodological issues are commonly cited as possible reasons for spot

74

production in negative control wells {Streeck, 2009 #1677}. Although the general

75

consensus is that high SFU in unstimulated wells are due to assay-specific problems

76

and should be excluded from analyses, ELISpot assays are not standardized and

77

exclusion criteria based on high background varies depending on protocols {Streeck,

78

2009 #1677;Cox, 2005 #1489;Immunotec, 2013 #1704}. However, biological factors

79

may also influence basal IFN-γ production detected ex vivo. Our group has repeatedly

80

observed dramatic differences in negative control IFN-γ responses from PBMC obtained

81

from two individuals tested on one ELISpot plate, where the only variation in assay

82

protocol occurred at the level of the sample. This observation propelled us to examine

83

correlates of spontaneous IFN-γ secretion in greater detail.

84
85

Studies have observed elevated immune activation among populations from
developing countries compared to North American or European cohorts and
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86

environmentally-driven factors, such as chronic infections, limited nutrition, and poor

87

hygienic conditions, have been proposed as possible explanations for these

88

findings{Rizzardini, 1998 #1639;Clerici, 2000 #1479;Lukwiya, 2001 #1582;Messele,

89

1999 #1404;Borkow, 2000 #1459;Koesters, 2004 #1400}. We hypothesized that there

90

may be a biological phenomenon mediated by increased immune activation that results

91

in increased IFN-γ secretion ex vivo, read out as higher SFU (background) in negative

92

controls wells of ELISpot assays. We conducted a cross-sectional study to assess the

93

prevalence of high background among HIV-1-seronegative couples and to identify

94

potentially modifiable biological correlates driving these background responses.

95
96

Materials and Methods

97

Study population

98

Couples in which both partners tested HIV-1-seronegative were recruited from

99

voluntary counseling and testing centers in Nairobi, Kenya from 2007-2009. Enrolled

100

couples reported having sex with their partner ≥3 times in the 3 months prior to

101

screening and did not report any outside sexual partnerships, and women participants

102

were not pregnant. Written informed consent was obtained from all study participants,

103

and ethical approval was received from the Institutional Review Boards at the University

104

of Washington and Kenyatta National Hospital. Couples were seen once in clinic at

105

enrollment. During this visit, clinical staff collected blood and genital specimens and

106

administered questionnaires to collect sociodemographic, sexual behavior, and self

107

reported medical history data.

108
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109
110

Laboratory procedures
Couples were determined to be concordantly HIV-1-seronegative using the

111

Determine HIV-1/2 rapid test (Abbott, Japan) and the Bioline HIV 1/2 rapid test

112

(Standard Diagnostics, Korea). HSV-2 serology was determined using the HerpeSelect

113

IgG ELISA kit (Focus Technologies, USA). Equivocal HSV-2 test results were analyzed

114

as either a negative or a positive result. Syphilis was tested using a rapid plasma reagin

115

(RPR) test (Becton Dickinson (BD), USA); reactive tests were confirmed by T. pallidum

116

haemagglutination assay (Randox, UK). For female participants the following tests were

117

conducted: urine pregnancy tests (Quick Vue One Step hCG Urine Pregnancy kit,

118

Quidel Corporation, USA), Trichomonas vaginalis cultures (In-Pouch TV, Biomed

119

Diagnostics, USA), and bacterial vaginosis (BV).

120
121

IFN-γ ELISpot assays

122

Blood samples from the couples were collected on the same day and batch

123

processed to reduce introduction of within-couple variability. ELISpot assays were

124

conducted to evaluate the frequency of background and antigen stimulated SFU with a

125

previously described protocol using Millipore plates (Millipore, USA) and Mabtech

126

(Mabtech, Sweden) reagents {Lohman, 2005 #1579}. One × 105 freshly isolated

127

peripheral blood mononuclear cells (PBMC)/well were stimulated with

128

phytohemagglutinin (PHA) (Murex Biotech Ltd, UK) in triplicate as positive control wells,

129

media alone in 9 negative control wells, or HIV-1 peptide pools in triplicate experimental

130

wells. Twenty-two peptide pools of 15-mers overlapping by 10 amino acids spanning the

131

HIV-1 genome were derived from the HIV-1 subtype A consensus sequence (Sigma-
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132

Gynosys, USA). Plates were read on a CTL ImmunoSpot S4 Core Analyzer, and

133

analyzed using ImmunoSpot Software (Cellular Technology Ltd, USA).

134

The background response, defined as the mean SFU in the 9 negative control

135

wells, was categorized as low (<50 SFU/106 PBMC) or high (≥50 SFU/106 PBMC).

136

Background responses were examined both as a dichotomous (pre-defined cutoffs

137

above) and continuous (magnitude of responses) variable. HIV-1-stimulated SFU were

138

defined as the average number of spots in triplicate wells minus background. IFN-γ

139

ELISpot responses were considered positive if experimental wells had ≥50 HIV-1-

140

stimulated SFU/106 PBMC and more than twice the background response. Individuals

141

were defined as positive ELISpot responders if they had ≥1 peptide pool with a positive

142

response.

143
144
145

Immune activation assays
Immune activation markers were measured on fresh whole blood specimens.

146

Specimens were stained with the following pre-mixed 4-color fluorochrome-conjugated

147

antibody combinations: anti-CD4-FITC, anti-CD38-PE, anti-CD3-PerCP, anti-HLA-DR-

148

APC and anti-CD8-FITC, anti-CD38-PE, anti-CD3-PerCP, anti-HLA-DR-APC (BD).

149

Specimens were run on a 4-color FACSCalibur flow cytometer (BD), and flow cytometry

150

data was analyzed and quality controlled using FlowJo software (Treestar, USA). Gates

151

were set conservatively to capture high-level expression of CD38/HLADR. Percentages

152

of activated cells, defined as CD38+HLA-DR+, CD38-HLA-DR+, or HLA-DR+ (CD38+ or

153

CD38-), in both CD4+ and CD8+ subsets were used in analyses.

154
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155

Statistical methods

156

Activated cells were compared between individuals with high and low

157

background responses and between positive and negative ELISpot responders using

158

Mann-Whitney U tests. Linear regression with robust standard errors was used to

159

assess correlates of background response. Data was log10 transformed when examining

160

magnitude of background SFU as a continuous variable to achieve a normal distribution.

161

A set of characteristics was selected a priori as potential correlates of immune activation.

162

Both partners of the couple reported number of sex acts with their study partner in the

163

past month, and the mean number of acts reported by the couple was used for analysis.

164

Also, any individual who self-reported having a fever, diarrhea, vomiting or a cough in

165

the past 3 months was considered to have a recent illness. To determine correlates of

166

immune activation, immune activation data was modeled as a proportion, and

167

multivariate analyses were performed for each characteristic adjusting for gender and

168

age using generalized linear models with logit link and robust standard errors. All

169

analyses were conducted using Stata version 11.2 statistical software (College Station,

170

USA).

171
172

Results

173

Study population characteristics

174

Fifty-eight individuals in monogamous, concordant HIV-1-seronegative

175

relationships were included in the analyses. Among these individuals, 29 (50%) were

176

females and the median age for all participants was 27 (interquartile range [IQR] 23-31)

177

(Table 1). Median length of cohabitation was 1 year (IQR 0-7). Participants reported a
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178

median of 4 lifetime sexual partners (IQR 3-6) and 5 sex acts (IQR 3-12) with their study

179

partner in the past month. From self-reporting, 43 (74%) had unprotected sex in the past

180

month, 12 (21%) had a history of sexually transmitted infections (STI), and 5 (9%) had

181

an illness (fever, diarrhea, vomiting, or cough) in the past 3 months. Twenty (35%)

182

individuals were HSV-2 seropositive or had an equivocal result, and 24 (83%) of the

183

men were circumcised. Among the women, 20 (69%) used birth control, the most

184

common form was oral, injectable or implanted hormonal contraceptives.

185
186
187

ELISpot background response and immune activation
Of the 58 low-risk participants, the median magnitude of background response

188

was 24 SFU/106 PBMC (IQR 10-44). Replicate spot counts per well based on input cell

189

number of 1 × 105 cells are shown in Figure 1a, demonstrating the range of individual

190

variability within the cohort. When ELISpot background responses were dichotomously

191

categorized, the majority (n=44,76%) individuals had low background secretion of INF-γ,

192

however 14 (24%) individuals were categorized as having high background with a

193

median of 61 SFU/106 PBMC (IQR 54-121), shown in detail in Figure 1b as partners

194

within each couple. Approximately half the individuals were in partnerships with other

195

‘high background’ individuals, while the other half were in partnerships with individuals

196

characterized as low background on the same plate, as shown in Figure 1c.

197

T cells were surface stained with immune activation markers CD38+ and HLA-

198

DR+ and analyzed to determine the level of immune activation. Depending on

199

differential CD38+ and HLA-DR+ phenotypes, 10-40% more CD8+ T cells expressed

200

markers of activation compared to CD4+ T cells (Figure 2). When compared by ELISpot

10

Liu, Amy Y

201

background response, frequency of CD4+ T cells co-expressing CD38+ and HLA-DR+

202

was significantly elevated in individuals with high background compared to those with

203

low background (p=0.02) (Figure 3a). Similarly, compared to individuals with low

204

background, those with high background had higher frequencies of CD8+ HLA DR+ T

205

cells with and without CD38 expression (p=0.02 and p=0.05, respectively) (Figure 3b).

206
207
208

Correlates of IFN-γ ELISpot background response
Univariate and multivariate models were used to evaluate the association

209

between ELISpot background, immune activation and sociodemographic variables.

210

ELISpot background was modeled as a continuous variable to increase the power of

211

detecting an association and because a biologically meaningful cutoff is not known.

212

Variables linked to infectious processes were associated with increased background. In

213

univariate models, individuals who reported a history of STI or recent illness had higher

214

magnitudes of log10 background SFU compared to those who did not (β=0.82, 95%

215

confidence interval [CI]=0.07-1.56, p=0.03; β=0.98, 95% CI=0.31-1.65, p=0.005,

216

respectively) (Table 2). There was also a trend toward higher log10 background SFU for

217

individuals who were HSV-2 positive or equivocal (p=0.07).

218

Furthermore, T cell activation was associated with higher magnitude of

219

background response, similar to the previous associations when background response

220

was examined as a dichotomous variable. Among CD4+ T cells, an increase in

221

proportions of CD38-HLA-DR+ and total HLA-DR+ cells were associated with an

222

increase in log10 background SFU (β=0.42, 95% CI=0.06-0.79, p=0.03; β=0.39, 95%

223

CI=0.08-0.71, p=0.02, respectively). Analogous associations were found with higher
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224

CD8+ T cell activation (CD38-HLA-DR+: β=0.16, 95% CI=0.04-0.28, p=0.008; HLA-DR+:

225

β=0.13, 95% CI=0.03-0.23, p=0.01). To determine whether immune activation or

226

infectious processes was driving the increased background responses, multivariate

227

analyses were conducted. Infectious processes and immune activation both remained

228

statistically significant correlates of magnitude of background SFU (range of p-values:

229

<0.001 – 0.05), except for the model including CD4+CD38+HLA-DR+ cells.

230
231
232

Correlates of immune activation
Having seen an association between T cell activation and IFN-γ ELISpot

233

background response, additional analyses were conducted to examine correlates of

234

immune activation. These analyses were adjusted for gender and age. Females were

235

more likely to have activated CD4+CD38-HLA-DR+ (aOR=0.73, 95% CI=0.58-0.91,

236

p=0.006) and total HLA-DR+ (aOR=0.68, 95% CI=0.52-0.87, p=0.002) compared to

237

males (Table 3). Additionally, trends were observed indicating that women who reported

238

any unprotected sex in the past month were more likely to have activated CD38 +HLA-

239

DR+ cells (p=0.10), and those who had BV were more likely to have a higher proportion

240

of cells expressing HLA-DR+ (p=0.09).

241

A different set of characteristics was observed to be associated with CD8+

242

immune activation. Circumcised men were less likely to have activated CD38+HLA-DR+

243

cells (aOR=0.55, 95% CI=0.32-0.94, p=0.03). Furthermore, there were trends for

244

females who were positive for BV to have increased proportions of total HLA-DR+ cells

245

(p=0.07) and for those who reported hormonal contraceptive use to have decreased

246

frequency of total HLA-DR+ cells (p=0.08).
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247
248
249

Background and immune activation by antigen-stimulated IFN-γ ELISpot response
To assess the association between immune activation and ELISpot response to

250

antigen-specific stimulation, levels of activated cells were compared between individuals

251

who had positive HIV-1 ELISpot results and those who had negative results. The

252

majority (50/58, 86%) had negative IFN-γ responses to HIV-1 peptides and 9 of these

253

50 (18%) had high background. In comparison 8 participants (14%) were categorized as

254

positive responders and among those 63% (5/8) had a high background response. Thus,

255

individuals with a high background response were ~7 times more likely to have a

256

positive IFN-γ ELISpot response to HIV peptide pools (OR=7.6, p=0.01). Additionally, a

257

strong positive correlation was seen between magnitude of background response and

258

magnitude of HIV-1-stimulated SFU (Spearman’s =0.43, p<0.001, data not shown).

259

Furthermore, CD38+HLADR+ expression in both CD4+ and CD8+ T cell subsets were

260

significantly elevated in individuals who had a positive ELISpot response compared to

261

those who did not (Figure 4). The association between presence of a positive response

262

and magnitude of background response remained statistically significant (p≤0.05) after

263

adjusting for frequency of CD8+HLADR+ activated cells, except when adjusting for the

264

CD4+HLA-DR+ phenotype, which showed a trend (p=0.08, data not shown).

265
266
267

Discussion
In this study we found of high spontaneous IFN-γ release in ELISpot assays

268

conducted on PBMC from ~25% of individuals and these individuals were more likely to

269

have elevated levels of immune activation in both CD4+ and CD8+ T cells. Naïve T cells
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270

differentiate into memory T cells after being activated {Hazenberg, 2000 #1530}, and

271

the activated effector cells are then responsible for producing cytokines in vivo, most

272

typically only during the acute immune response before the cells die or differentiate into

273

resting memory cells. As other studies in developing countries have speculated, our

274

participants are likely exposed to a wide spectrum of pathogens that may result in

275

persistent infections that cause chronic immune activation. Thus, these findings support

276

the hypothesis that highly activated T cells contribute to spontaneous IFN-γ production

277

ex vivo detected in IFN-γ release assays.

278

We found that a history of having a STI or an illness in the past 3 months was

279

significantly associated with high background SFU, even after adjusting for immune

280

activation. We expected these markers of infection to lead to an increase in activated

281

cells, and subsequently, elevated background response; however, the immune

282

activation markers that were measured may not have captured the whole T cell

283

activation pathway. In addition, since unfractionated PBMC were added to our ELISpot

284

assays, the cells of the innate immune system, particularly NK cells, may also be

285

responsible for IFN-γ production detected in the negative control wells {Dittrich, 2012

286

#1496}.

287

Interestingly, different correlates were found for high background response and

288

immune activation. Women had lower median frequencies of activated CD4+CD38-

289

HLADR+ cell phenotypes compared to men, which is consistent with a previous study

290

that found African American women had decreased levels of the immune activation

291

marker neopterin compared to African American men {Spencer, 2010 #1672re}. The

292

preponderance of HLA-DR+ cells relative to CD38+ populations was unexpected. Male
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293

circumcision was associated with decreased immune activation. Since results from

294

large randomized clinical trials showed a strong association between male circumcision

295

and protection against HIV-1 infection {Auvert, 2005 #1437;Bailey, 2007 #1440;Gray,

296

2007 #1521}, it is not surprising that circumcised men have lower levels of activated T

297

cells. Furthermore, this finding may provide an explanation as to why uncircumcised

298

men had a higher risk for HIV-1 infection in the Step Study {McElrath, 2008 #1595}.

299

To better understand the detection of HIV-1-stimuated responses in our HIV-1-

300

uninfected participants, we determined the effect of background SFU and immune

301

activation on the ELISpot response. We observed higher proportions of activated T cells

302

were associated with positive ELISpot responses. These results are similar to a

303

previous study that showed HIV-1-negative Kenyan women who had elevated T cell

304

immune activation expressed significantly increased IFN-γ production when stimulated

305

with superantigen staphylococcal enterotoxin B {Koesters, 2004 #1400}. Our results

306

suggest that either immune activation leads to non-specific IFN-γ release that may

307

interfere with the classification of having a positive response due to background (i.e.

308

false positives), or immune activation leads to higher levels of cross-reactivity to HIV-1

309

peptides. Furthermore, we found that individuals with higher background SFU were

310

more likely to have a higher magnitude HIV-1-stimulated response. When including both

311

background response and CD8+CD38+HLA-DR+ immune activation in the model for

312

predictors of a positive antigen stimulated ELISpot response, background remained the

313

only statistically significant predictor. The results from adjusted models suggest

314

activated T cells are hyper-responsive, secreting higher levels of cytokines when

315

stimulated, and thereby producing false positive ELISpot responses mediated through
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316

higher background responses. While these findings support the idea that activated cells

317

may have contributed to false positive HIV-1-specific cellular responses through

318

background response, it does not preclude the possibility of the participants being

319

unwilling to acknowledge exposure to HIV-1 from outside partnerships, exposure that

320

can lead to HIV-1 specific responses{Guthrie, 2012 #1525}.

321

Our data suggest criteria for defining positive ELISpot responses balance the risk

322

of false positive responses with the risk of introducing significant bias through the

323

selectively removal of data from individuals with high background. Chronic immune

324

activation can lead to immune dysfunctions such as anergy, activation-induced cell

325

death, cytokine dysregulation, and impaired signal transduction {Lukwiya, 2001

326

#1582;Bentwich, 1998 #1446;Alimonti, 2003 #1431;Leng, 2002 #1576}, and previous

327

studies have demonstrated the importance of the host’s pre-existing immune status in

328

influencing the efficacy of immune responses to vaccine or pathogen challenge {Borkow,

329

2002 #1458;Black, 2002 #1455}. It has been proposed that the activation state of the

330

participants may be a possible explanation for the unexpected increase in HIV-1

331

acquisition found in the Step study {Sekaly, 2008 #1661;McElrath, 2008 #1595}.

332

Individuals who have elevated immune activation levels may have difficulty mounting an

333

effective immune response, so excluding these individuals may significantly bias study

334

findings, especially for vaccine trials.

335

While a strength of this study was performing ELISpot assays on fresh samples

336

to optimize sensitivity, rerunning the assays on frozen aliquots may yield different

337

findings. Due to limited numbers of PBMC, we were not able to compare responses

338

between fresh and frozen samples. Another limitation of this study is the limited data on
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339

co-infections within this population. Helminth infections, malaria and TB are highly

340

endemic in Kenya and cause a chronic immune activation state, but we were unable to

341

diagnosis these conditions within this study.. Furthermore, unfractionated PBMC were

342

used in the assay, and together with the use of 15-mers peptides overlapping by 10

343

amino acids, the cell type responsible for IFN-γ secretion was not identified. While these

344

factors may limit the scope of our conclusions, they do not affect the foundational

345

findings.

346

In conclusion, our results suggest that elevated levels of immune activation,

347

along with previous infections, are associated with both higher background IFN-γ

348

secretion and positive HIV-1 stimulated ELISpot responses in a small but significant

349

percent of the general population. Additionally, different correlates were found to

350

contribute to T cell activation, highlighting the intricacies of the immune response. This

351

study indicates that conditions that lead to a persistently activated immune state in HIV-

352

1-seronegative individuals in Kenya can have a dramatic effect on immunological

353

assays, and as such, the pre-existing immune profile of populations should be

354

considered when developing and testing assays for measuring immunogenicity of

355

pathogens or potential vaccines.
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Figure Legends
Figure 1. Background response of ELISpot assays among HIV-1-uninfected
individuals. Negative control wells (replicates of 9) containing 105 PBMC and media
only were cultured overnight for determination of background IFN-γ response. A
reference line at 5 spots represents the cut-off number for categorizing a high (≥5
SFU/105 PBMC) vs. low (<5 SFU/105 PBMC) response. Individual wells (squares) and
mean ± SEM are shown per person. Individuals scoring positive for HIV peptide
responses (>2× background and ≥ 50 spots) are indicated in red. a) Range of IFN-γ
responses from 58 HIV-1-seronegative individuals. b) Couples in which one or both
individuals scored as high background by IFN-γ response. c) ELISpot plate images from
positive (columns 1-3) and negative control wells (columns 4-12) are shown for partners
(A and B) of a couple run with the same assay conditions. Partner A was categorized as
having a high background response and partner B as a low background response.

Figure 2. Example of staining profile for immune activation markers CD38+ and
HLA-DR+ on CD4+ and CD8+ T cells. CD38+ and HLA-DR+ staining among CD4+ and
CD8+ T cells for an individual. Quadrants were placed conservatively high as activated
cells generally have bright expression of these markers and this placement achieves a
restrictive estimate of activated cells, reducing the likelihood of falsely categorizing cells
as activated.

Figure 3. Immune activation markers by ELISpot background response.
Frequency of activated cells in (a) CD4+ T and (b) CD8+ T cell subsets are shown for
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individuals with low (grey box plot, <50 SFU/106 PBMC) and high (open box plot, ≥50
SFU/106 PBMC) background response. Upper, middle, and lower lines of the box show
group 75th percentile, median, and 25th percentile, respectively, individual outliers
indicated by solid circles. P-values compare the distribution of the percent of activated
cells for individuals with low background to those with high background, based on the
Mann-Whitney U test.

Figure 4. Immune activation markers by ELISpot response. Frequency of activated
cells in (a) CD4+ T and (b) CD8+ T cell subsets are shown for individuals with negative
(filled box) and positive (open box) ELISpot response, defined as 2-fold over
background and at least 50 SFU/106 cells. Upper, middle, and lower lines of the box
show group 75th percentile, median, and 25th percentile, respectively. P-values compare
the distribution of the percent of activated cells for individuals with negative response to
those with positive response, based on the Mann-Whitney U test
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Table 1. Cohort characteristics of concordant HIV-1-seronegative couples.
Characteristic

Median (IQR) or n (%)
(N=58)*
29 (50)
27 (23 - 31)
1 (0 - 7)
4 (3 - 6)
5 (3 -12)
43 (74)
12 (21)

Female
Age
Years living together
Lifetime sexual partners
Sex acts a
Any unprotected sex a
History of STI
HSV-2 serostatus
Negative
37 (65)
Equivocal
5 (9)
Positive
15 (26)
Bacterial vaginosis
5 (31)
Recent illness b
5 (9)
Male circumcision
24 (83)
Birth control use
20 (69)
Hormonal birth control use c
13 (45)
IQR, interquartile range; STI, sexually transmitted infection
* N=29 for characteristics unique to men or women. Bacterial vaginosis results were
available for 16 women.
a With study partner in the past month
b Reported fever, diarrhea, vomiting, or cough in the past 3 months
c Hormonal birth control use defined as oral, injectable, or implant contraceptives
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Table 2. Correlates of magnitude of ELISpot background responses.
Characteristic (N=58)*

Coeff

95% CI

pvalue

-0.03
0.03
-0.03
0.22
-0.001
0.54
0.82
0.60

-0.68 – 0.61
-0.14 – 0.20
-0.18 – 0.11
-0.42 – 0.87
-0.05 – 0.05
-0.19 – 1.27
0.07 – 1.56
-0.05 – 1.25

0.92
0.73
0.64
0.49
0.97
0.15
0.03
0.07

-0.31
0.98
-0.35
-0.58
0.76
0.42
0.39
0.23
0.16
0.13

-1.45 – 0.83
0.31 – 1.65
-1.27 – 0.56
-1.51 – 0.36
-0.44 – 1.96
0.06 – 0.79
0.08 – 0.71
-0.05 – 0.51
0.04 – 0.28
0.03 – 0.23

0.57
0.005
0.43
0.22
0.21
0.03
0.02
0.10
0.008
0.01

Multivariate Analyses g
History of STI
Recent illness
CD4+CD38+HLA-DR+

0.70
0.95
0.82

0.07 – 1.33
0.03
0.51 – 1.39 <0.001
-0.28 – 1.92
0.14

Recent illness
CD4+CD38-HLA-DR+

0.92
0.40

0.37 – 1.46
0.05 – 0.75

0.001
0.03

Recent illness
CD4+HLA-DR+

0.96
0.39

0.45 – 1.48
0.08 – 0.69

<0.001
0.01

History of STI
Recent illness
CD8+CD38+HLA-DR+

0.73
0.95
0.27

0.06 – 1.40
0.48 – 1.42
0.00 – 0.53

0.03
<0.001
0.05

History of STI
Recent illness
CD8+CD38-HLA-DR+

0.67
0.91
0.17

0.02 – 1.32
0.48 – 1.34
0.05 – 0.28

0.04
<0.001
0.004

History of STI
Recent illness

0.68
0.95

0.05 – 1.32
0.52 – 1.39

0.04
<0.001

Univariate Analyses a
Female
Age (per 5 years)
Years living together
High sexual partners b
Sex acts c
Any unprotected sex c
History of STI
HSV-2 seropositive (positive or
equivocal) d
Bacterial vaginosis
Recent illness e
Male circumcision
Hormonal birth control use f
CD4+CD38+HLA-DR+
CD4+CD38-HLA-DR+
CD4+HLA-DR+
CD8+CD38+HLA-DR+
CD8+CD38-HLA-DR+
CD8+HLA-DR+
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CD8+HLA-DR+

0.13

0.04 – 0.23

0.005

Coeff = beta coefficient from regression model; CI = confidence interval; STI = sexually
transmitted infections
* N=29 for characteristics unique to men or women. Bacterial vaginosis results were
available for 16 women.
a Association

between log10 background SFU and each covariate is examined

separately in unadjusted models
b Lifetime
c With

sexual partners dichotomized at median: <4 and ≥4

study partner in the past month

d HSV-2

seropositive defined as positive or equivocal HSV-2 test results

e Reported

fever, diarrhea, vomiting, or cough in the past 3 months

f Hormonal

birth control use defined as oral contraceptives, injectables, or implants

g Multivariate

analyses included history of STI, recent illness, and immune activation as

covariates; models with CD4+C38-HLA-DR+ and CD4+HLA-DR+ cells only included
recent illness due to co-linearity with history of STI
BOLD indicates p≤0.05
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